coumarin has been researched along with Breast Neoplasms in 22 studies
2H-chromen-2-one: coumarin derivative
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Coumarin is not effective therapy for women who have lymphedema of the arm after treatment for breast cancer." | 9.09 | Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. ( Kugler, JW; Levitt, R; Loprinzi, CL; Michalak, JC; Mowat, RB; Novotny, P; Quella, SK; Rooke, TW; Sloan, JA; Stella, PJ; Tschetter, LK; Windschitl, H, 1999) |
| "In a randomized, double-blind, parallel group study, we compared the clinical efficacy of coumarin 90 mg/day (Group A) with 135 mg/day (Group B) in 77 women (age 35-65 years) with lymphedema of the upper limb secondary to surgery and irradiation for treatment of breast cancer." | 9.09 | Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer. ( Alcaide, A; Alcoba, C; Azcona, JM; Burgos, A; Garrido, J; Lorente, C; Moreno, E; Murillo, E; Olsina-Kissler, J; Olsina-Pavia, J; Samaniego, E; Serra, M, 1999) |
| "Acquired resistance to fulvestrant and palbociclib is a new challenge to treatment of estrogen receptor positive (ER+) breast cancer." | 7.96 | Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. ( Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J, 2020) |
| "The present investigation aimed to examine the therapeutic potential of the new coumarin derivative bis(4-hydroxy-2H-chromen-2-one) coumarin (4HC) against breast cancer." | 7.91 | Bis(4-hydroxy-2H-chromen-2-one) Coumarin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Aromatase Inhibition. ( Bachari, K; Berry, A; Caldefie-Chézet, F; Decombat, C; Delort, L; Ramdani, LH; Silva, A; Talhi, O; Vasson, MP; Vermerie, M, 2019) |
| "Styrene substituted biscoumarin could induce apoptosis through intrinsic mitochondrial pathway in breast cancer cell lines, particularly in MDA-MB-231." | 7.85 | Cellular effect of styrene substituted biscoumarin caused cellular apoptosis and cell cycle arrest in human breast cancer cells. ( Balusamy, SR; Kandaswamy, N; Periyathambi, D; Perumalsamy, H; Raveendiran, N; Sankarapandian, K, 2017) |
| " A series of osthole derivatives bearing aryl substituents at 3-position of coumarin, has been prepared and evaluated for their growth inhibitory activity against human breast cancer cell lines MCF-7 and MDA-MB-231." | 7.76 | Discovery of novel osthole derivatives as potential anti-breast cancer treatment. ( An, R; Li, Y; Wang, X; You, L, 2010) |
| "Of particular interest in breast cancer chemotherapy, some coumarins and their active metabolite 7-hydroxycoumarin analogs have shown sulfatase and aromatase inhibitory activities." | 6.44 | A review of coumarin derivatives in pharmacotherapy of breast cancer. ( Cooperwood, JS; Khan, MO; Musa, MA, 2008) |
| "The activity of potent compounds on breast cancer cells cultured more similarly to the conditions of the tumour microenvironment was also investigated, and increased toxicity was observed." | 5.62 | Investigation of the cytotoxicity of bioinspired coumarin analogues towards human breast cancer cells. ( Butterworth, S; Detsi, A; Garzon Sanz, M; Gkionis, L; Kalospyros, A; Kavetsou, E; Manousakis, D; Tirella, A, 2021) |
| "Coumarin is not effective therapy for women who have lymphedema of the arm after treatment for breast cancer." | 5.09 | Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. ( Kugler, JW; Levitt, R; Loprinzi, CL; Michalak, JC; Mowat, RB; Novotny, P; Quella, SK; Rooke, TW; Sloan, JA; Stella, PJ; Tschetter, LK; Windschitl, H, 1999) |
| "In a randomized, double-blind, parallel group study, we compared the clinical efficacy of coumarin 90 mg/day (Group A) with 135 mg/day (Group B) in 77 women (age 35-65 years) with lymphedema of the upper limb secondary to surgery and irradiation for treatment of breast cancer." | 5.09 | Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer. ( Alcaide, A; Alcoba, C; Azcona, JM; Burgos, A; Garrido, J; Lorente, C; Moreno, E; Murillo, E; Olsina-Kissler, J; Olsina-Pavia, J; Samaniego, E; Serra, M, 1999) |
| "Acquired resistance to fulvestrant and palbociclib is a new challenge to treatment of estrogen receptor positive (ER+) breast cancer." | 3.96 | Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. ( Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J, 2020) |
| "The present investigation aimed to examine the therapeutic potential of the new coumarin derivative bis(4-hydroxy-2H-chromen-2-one) coumarin (4HC) against breast cancer." | 3.91 | Bis(4-hydroxy-2H-chromen-2-one) Coumarin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Aromatase Inhibition. ( Bachari, K; Berry, A; Caldefie-Chézet, F; Decombat, C; Delort, L; Ramdani, LH; Silva, A; Talhi, O; Vasson, MP; Vermerie, M, 2019) |
| "Styrene substituted biscoumarin could induce apoptosis through intrinsic mitochondrial pathway in breast cancer cell lines, particularly in MDA-MB-231." | 3.85 | Cellular effect of styrene substituted biscoumarin caused cellular apoptosis and cell cycle arrest in human breast cancer cells. ( Balusamy, SR; Kandaswamy, N; Periyathambi, D; Perumalsamy, H; Raveendiran, N; Sankarapandian, K, 2017) |
| " A series of osthole derivatives bearing aryl substituents at 3-position of coumarin, has been prepared and evaluated for their growth inhibitory activity against human breast cancer cell lines MCF-7 and MDA-MB-231." | 3.76 | Discovery of novel osthole derivatives as potential anti-breast cancer treatment. ( An, R; Li, Y; Wang, X; You, L, 2010) |
| "Coumarin is a bicyclic oxygen bearing heterocyclic scaffold formed by fusion of benzene with the pyrone ring." | 2.82 | Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview. ( Das, S; Kulkarni, S; Liang, C; Mishra, PK; Ratre, P; Thareja, S, 2022) |
| "Estrogen-dependent breast cancer (EDBC) is a kind of common malignant tumor in postmenopausal women with growing tendency in recent years." | 2.46 | Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer. ( Jiao, J; Liao, Q; Xiang, H, 2010) |
| "Of particular interest in breast cancer chemotherapy, some coumarins and their active metabolite 7-hydroxycoumarin analogs have shown sulfatase and aromatase inhibitory activities." | 2.44 | A review of coumarin derivatives in pharmacotherapy of breast cancer. ( Cooperwood, JS; Khan, MO; Musa, MA, 2008) |
| "The activity of potent compounds on breast cancer cells cultured more similarly to the conditions of the tumour microenvironment was also investigated, and increased toxicity was observed." | 1.62 | Investigation of the cytotoxicity of bioinspired coumarin analogues towards human breast cancer cells. ( Butterworth, S; Detsi, A; Garzon Sanz, M; Gkionis, L; Kalospyros, A; Kavetsou, E; Manousakis, D; Tirella, A, 2021) |
| "Moreover, SV37 inhibits growth of breast cancer cell lines." | 1.42 | A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death. ( Bagrel, D; Bana, E; Cerella, C; Chaimbault, P; Dicato, M; Diederich, M; Kirsch, G; Sibille, E; Valente, S, 2015) |
| "Development of new, targeted antibreast cancer drug which can treat both the hormone receptor (positive and negative) breast cancers is a very challenging task." | 1.39 | Discovery of coumarin-monastrol hybrid as potential antibreast tumor-specific agent. ( Avula, SR; Bathula, SR; Palnati, GR; Sashidhara, KV; Sharma, K, 2013) |
| "This coumarin has been shown not to be cytotoxic at up to 40 mum." | 1.32 | Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. ( Chen, S; Cho, M; Karlsberg, K; Yuan, YC; Zhou, D, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 2 |
| Zhao, J | 1 |
| Gutgesell, LM | 1 |
| Shen, Z | 1 |
| Ratia, K | 1 |
| Dye, K | 1 |
| Dubrovskyi, O | 1 |
| Zhao, H | 1 |
| Huang, F | 1 |
| Tonetti, DA | 1 |
| Thatcher, GRJ | 1 |
| Xiong, R | 1 |
| Ratre, P | 2 |
| Kulkarni, S | 2 |
| Das, S | 2 |
| Liang, C | 2 |
| Mishra, PK | 2 |
| Thareja, S | 2 |
| Ramdani, LH | 1 |
| Talhi, O | 1 |
| Decombat, C | 1 |
| Vermerie, M | 1 |
| Berry, A | 1 |
| Silva, A | 1 |
| Bachari, K | 1 |
| Vasson, MP | 1 |
| Delort, L | 1 |
| Caldefie-Chézet, F | 1 |
| Gkionis, L | 1 |
| Kavetsou, E | 1 |
| Kalospyros, A | 1 |
| Manousakis, D | 1 |
| Garzon Sanz, M | 1 |
| Butterworth, S | 1 |
| Detsi, A | 1 |
| Tirella, A | 1 |
| Perumalsamy, H | 1 |
| Sankarapandian, K | 1 |
| Kandaswamy, N | 1 |
| Balusamy, SR | 1 |
| Periyathambi, D | 1 |
| Raveendiran, N | 1 |
| Bana, E | 1 |
| Sibille, E | 1 |
| Valente, S | 1 |
| Cerella, C | 1 |
| Chaimbault, P | 1 |
| Kirsch, G | 1 |
| Dicato, M | 1 |
| Diederich, M | 1 |
| Bagrel, D | 1 |
| Draoui, N | 1 |
| Schicke, O | 1 |
| Seront, E | 1 |
| Bouzin, C | 1 |
| Sonveaux, P | 1 |
| Riant, O | 1 |
| Feron, O | 1 |
| Lim, SY | 1 |
| Chung, WY | 1 |
| Lee, HK | 1 |
| Park, MS | 1 |
| Park, HG | 1 |
| Musa, MA | 1 |
| Cooperwood, JS | 1 |
| Khan, MO | 1 |
| Jiao, J | 1 |
| Xiang, H | 1 |
| Liao, Q | 1 |
| You, L | 1 |
| An, R | 1 |
| Wang, X | 1 |
| Sashidhara, KV | 1 |
| Avula, SR | 1 |
| Sharma, K | 1 |
| Palnati, GR | 1 |
| Bathula, SR | 1 |
| Boursier, V | 1 |
| Koshy, L | 1 |
| Dwarakanath, BS | 1 |
| Raj, HG | 1 |
| Chandra, R | 1 |
| Mathew, TL | 1 |
| Chen, S | 1 |
| Cho, M | 1 |
| Karlsberg, K | 1 |
| Zhou, D | 1 |
| Yuan, YC | 1 |
| Lin, PH | 1 |
| Lin, CH | 1 |
| Huang, CC | 1 |
| Chuang, MC | 1 |
| Lin, P | 1 |
| Mäkelä, S | 1 |
| Poutanen, M | 1 |
| Lehtimäki, J | 1 |
| Kostian, ML | 1 |
| Santti, R | 1 |
| Vihko, R | 1 |
| Loprinzi, CL | 2 |
| Sloan, J | 1 |
| Kugler, J | 1 |
| Kugler, JW | 1 |
| Sloan, JA | 1 |
| Rooke, TW | 1 |
| Quella, SK | 1 |
| Novotny, P | 1 |
| Mowat, RB | 1 |
| Michalak, JC | 1 |
| Stella, PJ | 1 |
| Levitt, R | 1 |
| Tschetter, LK | 1 |
| Windschitl, H | 1 |
| Ganz, PA | 1 |
| Burgos, A | 1 |
| Alcaide, A | 1 |
| Alcoba, C | 1 |
| Azcona, JM | 1 |
| Garrido, J | 1 |
| Lorente, C | 1 |
| Moreno, E | 1 |
| Murillo, E | 1 |
| Olsina-Pavia, J | 1 |
| Olsina-Kissler, J | 1 |
| Samaniego, E | 1 |
| Serra, M | 1 |
| Alder, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study Evaluating the Safety of Bevacizumab in Women With a History of Breast Cancer Suffering From Moderate to Severe Upper Extremity Lymphedema[NCT00318513] | Phase 1 | 35 participants | Interventional | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for coumarin and Breast Neoplasms
| Article | Year |
|---|---|
Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chemistry, Pharmaceutical; | 2022 |
Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chemistry, Pharmaceutical; | 2022 |
Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chemistry, Pharmaceutical; | 2022 |
Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chemistry, Pharmaceutical; | 2022 |
A review of coumarin derivatives in pharmacotherapy of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Coumarins; Enzyme Inhibitors; Estrogens; Humans; Selective | 2008 |
Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chromones; Coumarins; Fema | 2010 |
[Lymphedema: which drug therapy?].
Topics: Anticoagulants; Breast Neoplasms; Coumarins; Diuretics; Female; Flavonoids; Humans; Lymphedema | 2002 |
2 trials available for coumarin and Breast Neoplasms
| Article | Year |
|---|---|
Lack of effect of coumarin in women with lymphedema after treatment for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Coumar | 1999 |
Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer.
Topics: Arm; Breast Neoplasms; Combined Modality Therapy; Coumarins; Dose-Response Relationship, Drug; Doubl | 1999 |
16 other studies available for coumarin and Breast Neoplasms
| Article | Year |
|---|---|
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models | 2020 |
Bis(4-hydroxy-2H-chromen-2-one) Coumarin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Aromatase Inhibition.
Topics: Apoptosis; Aromatase; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Cell Proliferation; Chromones | 2019 |
Investigation of the cytotoxicity of bioinspired coumarin analogues towards human breast cancer cells.
Topics: Biomimetic Materials; Breast Neoplasms; Cell Death; Cell Line, Tumor; Coumarins; Drug Design; Female | 2021 |
Cellular effect of styrene substituted biscoumarin caused cellular apoptosis and cell cycle arrest in human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Movement; Cell Prol | 2017 |
A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death.
Topics: Apoptosis; Benzoquinones; Breast Neoplasms; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation | 2015 |
Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux.
Topics: Animals; Breast Neoplasms; Colorectal Neoplasms; Coumarins; Female; HCT116 Cells; Humans; Lactic Aci | 2014 |
Direct and nondestructive verification of PNA immobilization using click chemistry.
Topics: Acetylene; Azides; Breast Neoplasms; Coumarins; DNA Mutational Analysis; Fluorescent Dyes; Genes, BR | 2008 |
Discovery of novel osthole derivatives as potential anti-breast cancer treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cnidium; Coumarins; Female; Humans | 2010 |
Discovery of coumarin-monastrol hybrid as potential antibreast tumor-specific agent.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; C | 2013 |
Suicidal oxidative stress induced by certain antioxidants.
Topics: Antioxidants; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Coumarins; Female; Glioma; Hum | 2003 |
Biochemical and biological characterization of a novel anti-aromatase coumarin derivative.
Topics: Androgens; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell C | 2004 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines.
Topics: Benzamides; Benzoflavones; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Survival; Coumarins; | 2007 |
Estrogen-specific 17 beta-hydroxysteroid oxidoreductase type 1 (E.C. 1.1.1.62) as a possible target for the action of phytoestrogens.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Division; Coumarins; Estradiol; Estrogens, | 1995 |
Coumarin-induced hepatotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Coumarins; Female; | 1997 |
The quality of life after breast cancer--solving the problem of lymphedema.
Topics: Breast Neoplasms; Coumarins; Female; Humans; Lymph Node Excision; Lymphedema; Postoperative Complica | 1999 |
Guidelines for the surgical management of breast cancer: comment.
Topics: Anticoagulants; Breast Neoplasms; Coumarins; Female; Humans; Lymphedema; Postoperative Complications | 1999 |